Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Kees

Showing results (211-220 of 376) with videos related to

Pageof 38
Sort By:
Arteriosclerosis, Thrombosis, and Vascular Biology|March 11, 2021
ANGPTL3 Inhibition With Evinacumab Results in Faster Clearance of IDL and LDL apoB in Patients With Homozygous Familial Hypercholesterolemia-Brief ReportLaurens F Reeskamp, John S Millar, Liya Wu, et al.
The British Journal of Surgery|March 2, 2022
Successful surgical-multimodal treatment for vaccine-induced complete splanchnic vein thrombosis after ChAdOx1 nCoV-19 vaccinationHenrik Junger, Lukas Luerken, Martin G Kees, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|August 30, 2005
Consequences of cholesteryl ester transfer protein inhibition in patients with familial hypoalphalipoproteinemiaRadjesh J Bisoendial, G Kees Hovingh, Karim El Harchaoui, et al.
Journal of Clinical Lipidology|May 16, 2017
Plasma lipoprotein(a) levels in patients with homozygous autosomal dominant hypercholesterolemiaBarbara Sjouke, Reyhana Yahya, Michael W T Tanck, et al.
Atherosclerosis|October 20, 2012
Patients with low HDL-cholesterol caused by mutations in LCAT have increased arterial stiffnessBas van den Bogaard, Adriaan G Holleboom, Raphaël Duivenvoorden, et al.
Atherosclerosis|August 17, 2024
Plasma C-reactive protein is associated with a pro-inflammatory and adverse plaque phenotypeJordan M Kraaijenhof, Barend M Mol, Nick S Nurmohamed, et al.
European Heart Journal. Cardiovascular Imaging|December 10, 2024
Plasma proteomics improves prediction of coronary plaque progressionJordan M Kraaijenhof, Nick S Nurmohamed, Michiel J Bom, et al.
Lancet (London, England)|March 7, 2015
Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 studyJohn J P Kastelein, Joost Besseling, Sukrut Shah, et al.
Journal of the American College of Cardiology|February 15, 2020
Long-Term Evolocumab in Patients With Familial HypercholesterolemiaRaul D Santos, Evan A Stein, G Kees Hovingh, et al.
Atherosclerosis|February 18, 2021
Intronic variant screening with targeted next-generation sequencing reveals first pseudoexon in LDLR in familial hypercholesterolemiaLaurens F Reeskamp, Manon Balvers, Jorge Peter, et al.
Pageof 38

Showing results (211-220 of 376) with videos related to

Sort By:
Pageof 38
Arteriosclerosis, Thrombosis, and Vascular Biology|March 11, 2021
ANGPTL3 Inhibition With Evinacumab Results in Faster Clearance of IDL and LDL apoB in Patients With Homozygous Familial Hypercholesterolemia-Brief ReportLaurens F Reeskamp, John S Millar, Liya Wu, et al.
The British Journal of Surgery|March 2, 2022
Successful surgical-multimodal treatment for vaccine-induced complete splanchnic vein thrombosis after ChAdOx1 nCoV-19 vaccinationHenrik Junger, Lukas Luerken, Martin G Kees, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|August 30, 2005
Consequences of cholesteryl ester transfer protein inhibition in patients with familial hypoalphalipoproteinemiaRadjesh J Bisoendial, G Kees Hovingh, Karim El Harchaoui, et al.
Journal of Clinical Lipidology|May 16, 2017
Plasma lipoprotein(a) levels in patients with homozygous autosomal dominant hypercholesterolemiaBarbara Sjouke, Reyhana Yahya, Michael W T Tanck, et al.
Atherosclerosis|October 20, 2012
Patients with low HDL-cholesterol caused by mutations in LCAT have increased arterial stiffnessBas van den Bogaard, Adriaan G Holleboom, Raphaël Duivenvoorden, et al.
Atherosclerosis|August 17, 2024
Plasma C-reactive protein is associated with a pro-inflammatory and adverse plaque phenotypeJordan M Kraaijenhof, Barend M Mol, Nick S Nurmohamed, et al.
European Heart Journal. Cardiovascular Imaging|December 10, 2024
Plasma proteomics improves prediction of coronary plaque progressionJordan M Kraaijenhof, Nick S Nurmohamed, Michiel J Bom, et al.
Lancet (London, England)|March 7, 2015
Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 studyJohn J P Kastelein, Joost Besseling, Sukrut Shah, et al.
Journal of the American College of Cardiology|February 15, 2020
Long-Term Evolocumab in Patients With Familial HypercholesterolemiaRaul D Santos, Evan A Stein, G Kees Hovingh, et al.
Atherosclerosis|February 18, 2021
Intronic variant screening with targeted next-generation sequencing reveals first pseudoexon in LDLR in familial hypercholesterolemiaLaurens F Reeskamp, Manon Balvers, Jorge Peter, et al.
Pageof 38